Table 3 Serum albumin value at 6 months after chemotherapy
From: Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
Well-nourished (n = 67) | Bad-nourished (n = 41) | p value | ||
|---|---|---|---|---|
Age | (Median, range) | 64 (35–80) | 68 (34–83) | 0.23 |
Gender | 37 | 21 | 0.68 | |
WHO performance status | (> 2) | 6 (9.0%) | 16 (39.0) | < 0.01 |
Body mass indexa | (Median, range) | 24.1 (17.9–35.0) | 23.1 (20.1–28.8) | 0.67 |
Perioral food intake | 67 (100%) | 36 (87.9%) | 0.02 | |
Primary site | ||||
Rectum | 22 | 18 | 0.25 | |
Right-sided | (n = 51) | 26 | 24 | 0.04 |
Left-sided | (n = 57) | 44 | 13 | < 0.01 |
Residual of primary tumor | 13 | 4 | 0.18 | |
Continuing regimen | ||||
FOLFOX/FOLFIRI | 16/51 | 13/29 | 0.38 | |
Performing chemotherapy cycles during 6 months | 21 (6–24) | 11 (4–24) | < 0.01 | |
Add-on targeting agent | ||||
VEGFR | (n = 48) | 34 (50.7%) | 14 (34.1%) | 0.09 |
EGFR | (n = 26) | 11 (16.4%) | 15 (36.6%) | 0.02 |
None | (n = 34) | 22 (32.8%) | 12 (29.3%) | 0.7 |
Adverse event | ||||
Hematotoxicity | ||||
Grade 2 | 21 (31.3%) | 20 (48.8%) | 0.18 | |
Grade 3 | 6 (9.0%) | 8 (19.5%) | 0.03 | |
Grade 4 | 0 (0%) | 1 (2.4%) | 0.72 | |
Non-hematotoxicity | ||||
Grade 2 | 21 (31.3%) | 21 (51.2%) | 0.04 | |
Grade 3 | 4 (6.0%) | 10 (24.4%) | < 0.01 | |
Grade 4 | 1 (1.5%) | 1 (2.4%) | 0.73 | |
Discontinueb | 4 | 14 | < 0.01 | |
Dose reduction | 4 | 10 | < 0.01 | |
Conversion to surgical treatment | 6 | 1 | < 0.18 | |
Tumor markerc | ||||
CEA (mg/L) | 5.3 (2.85–15.05) | 27.75 (7.98–78.9) | < 0.01 | |
CA19-9 (mg/L) | 15 (7.05–71.25) | 33.3 (6.15–1040.13) | 0.25 | |